Edaravone inhibits the disease activity in rheumatoid arthritis.
A male patient with rheumatoid arthritis (RA) developed acute stroke and was treated with the free radical scavenger, edaravone. Polyarthralgia improved with a reduction in serum C-reactive protein concentration soon after the start of edaravone administration. The disease activity score 28 (DAS28) also decreased. Edaravone appears to be effective for the control of RA. The usefulness of this potentially novel therapeutic agent should be tested in a well designed randomized controlled trial.
Arii
Kaoru
K
Department of Endocrinology, Metabolism and Nephrology, Kochi Medical School, Kochi University, Japan. ariik@med.kochi-u.ac.jp
Kumon
Yoshitaka
Y
Ikeda
Yukio
Y
Suehiro
Tadashi
T
Hashimoto
Kozo
K
D000983:Antipyrine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D002097:C-Reactive Protein / Q000378:metabolism; D000077553:Edaravone; D016166:Free Radical Scavengers / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D020521:Stroke / Q000150:complications
D016166:Free Radical Scavengers; D002097:C-Reactive Protein; D000077553:Edaravone; D000983:Antipyrine